MADE Institutional Ownership

ISHARES US MANUFACTURING

Latest close $38.52 as of Aug 4, 2026

MADE institutional ownership at a glance

Follow ISHARES US MANUFACTURING institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: BlackRock filed Schedule 13G amendment on Dec 6, 2024, reporting 178.0K shares and 49.40% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing Dec 6, 2024

Public consensus preview Reduction leaning 37/100 institutional research score

1 tracked institution Latest filing Dec 6, 2024

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week range data is not available for this security yet.

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Nov 30, 2024

BlackRock Dec 6, 2024 filed

BlackRock Aug 7, 2024 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 3 filing(s)

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
BlackRock CIK0002012383	Nov 30, 2024 observed Dec 6, 2024 filed · 6d Schedule 13G amendment	Earliest Schedule 13G amendment found	178.0K	49.40%	$26.90	$26.45	$38.52
BlackRock CIK0002012383	Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence	Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal.	210.0K				$38.52
BlackRock CIK0001364742	Jul 31, 2024 observed Aug 7, 2024 filed · 7d Initial Schedule 13G	Initial Schedule 13G	210.0K	87.50%	$24.13	$22.33	$38.52

Explore more institutional activity

Related research

Compare MADE with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

VERA VERA THERAPEUTICS INC 37/100 Reduction leaning NOKBF NOKIA OYJ 37/100 Reduction leaning REZI RESIDEO TECHNOLOGIES, INC. 37/100 Reduction leaning VTRS Viatris Inc 37/100 Reduction leaning

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026